Arcadia Biosciences

Arcadia Biosciences, Inc. is an agricultural biotechnology company, which engages in the development of agricultural products. It uses screening, breeding, and biotechnology techniques to create agricultural products for consumers, processors, and farmers. Its products include GoodWheat pasta, Zola coconut water, ProVault topical pain relief, and SoulSpring bath and body care. The company was founded by Eric J. Rey and John G. Sperling in 2002 and is headquartered in Davis, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Arcadia Biosciences reports positive Q1 results, eyes revenue growth

Arcadia Biosciences delivered strong financial performance in Q1 2024, driven by revenue growth and cost management. The company faces challenges in retail execution but has opportunities for revenue growth through brand expansions and strategic partnerships.

Arcadia Biosciences reports strong Q2 driven by Zola growth

Arcadia Biosciences delivered solid financial performance in Q2 2024 driven by Zola Coconut Water.
Efficient cost-saving measures and strategic asset monetization bolstered profitability.
Challenges include managing increased costs and sustaining growth momentum.
Opportunities lie in expanding Zola brand, diversifying revenue streams, and strategic partnerships.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Arcadia Biosciences, Inc. is an agricultural biotechnology company, which engages in the development of agricultural products. It uses screening, breeding, and biotechnology techniques to create agricultural products for consumers, processors, and farmers. Its products include GoodWheat pasta, Zola coconut water, ProVault topical pain relief, and SoulSpring bath and body care. The company was founded by Eric J. Rey and John G. Sperling in 2002 and is headquartered in Dallas, TX.

DALLAS--(BUSINESS WIRE)--Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative, plant-based health and wellness products, today announced that it will release its financial and business results for the third quarter of 2024 after market close on November 12, 2024. The company has scheduled a conference call for 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss third-quarter results and key strategic achievements. Interested participants can join the conferenc.

Arcadia Biosciences (RKDA) Announces Date of Third Quarter 2024 Financial Results and Business Highlights Conference Call

Bunge Global SA

Hydrofarm Holdings Group

West Fraser Timber Co. Ltd.

The near-term outlook for the Zacks Agriculture - Products industry is uncertain due to low commodity prices and inflated costs. Investors should watch BG, WFG, HYFM and RKDA, which are braving the industry headwinds.

4 Agriculture - Products Stocks to Watch Despite Industry Concerns

Arcadia Biosciences (RKDA) witnesses a solid 42% improvement in Zola sales in Q2. The company continues to invest to grow the Zola brand through mass market retailers and grocery store chains.

Arcadia Biosciences (RKDA) Q2 Earnings Miss, Increase Y/Y

Arcadia Biosciences, Inc. (NASDAQ:RKDA ) Q2 2024 Earnings Conference Call August 13, 2024 4:30 PM ET Company Participants Mark Kawakami - CFO T.J. Schaefer - President & CEO Conference Call Participants Raghuram Selvaraju - H.C.

Arcadia Biosciences, Inc. (RKDA) Q2 2024 Earnings Call Transcript

Arcadia Biosciences (RKDA) came out with quarterly earnings of $0.78 per share, missing the Zacks Consensus Estimate of $1.27 per share. This compares to loss of $2.64 per share a year ago.

Arcadia Biosciences (RKDA) Q2 Earnings Miss Estimates

DALLAS--(BUSINESS WIRE)--Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative, plant-based health and wellness products, today released its financial and business results for the second quarter and first half of 2024. “The second quarter of 2024 was a significant turning point for Arcadia as we transform the business and chart our path to becoming cash flow positive,” said T.J. Schaefer, president and CEO. “We monetized our wheat IP through two transactions: selling.

Arcadia Biosciences (RKDA) Announces Second-Quarter and First-Half 2024 Financial Results and Business Highlights

Vertex Pharmaceuticals

LOS ANGELES--(BUSINESS WIRE)--Prime Therapeutics Fails to Silence AHF in PBM Price-Fixing Arbitration.

Prime Therapeutics Fails to Silence AHF in PBM Price-Fixing Arbitration

DALLAS--(BUSINESS WIRE)--Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative, plant-based health and wellness products, today announced that it will release its financial and business results for the second quarter and first half of 2024 after market close on August 13, 2024. The company has scheduled a conference call for 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss second-quarter results and key strategic achievements. Interested participants can joi.

Arcadia Biosciences (RKDA) Announces Date of Second Quarter 2024 Financial Results and Business Highlights Conference Call

Arcadia Biosciences (RKDA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Arcadia Biosciences (RKDA) Upgraded to Strong Buy: Here's What You Should Know

Cinemark Holdings

CALABASAS HILLS, Calif.--(BUSINESS WIRE)--The Cheesecake Factory® is celebrating its favorite holiday – National Cheesecake Day – in a big way this year making it a two-day celebration and introducing the newest flavor to its legendary lineup on July 29: Triple Berry Bliss Cheesecake – creamy cheesecake layered with vanilla cake, three kinds of berries and a kiss of citrus. For every slice of Triple Berry Bliss Cheesecake sold through July 29, 2025, The Cheesecake Factory will donate 25 cents t.

The Cheesecake Factory Offers Triple the Reasons to Celebrate National Cheesecake Day This Year

DALLAS--(BUSINESS WIRE)--Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative, plant-based health and wellness products, announced that CEO Stan Jacot has left the company and been replaced by Thomas J. Schaefer, effective July 5, 2024. Schaefer was previously Arcadia's chief financial officer and will be replaced in that role by Mark Kawakami, Arcadia's current vice president of finance. “On behalf of Arcadia, I would like to thank Stan for his many contributions to.

Arcadia Biosciences (RKDA) Announces Leadership Transition

Arcadia Biosciences (RKDA) sells its GoodWheat brand to scale up its wheat IP.

Arcadia Biosciences (RKDA) Sells GoodWheat Brand to Above Food

DALLAS--(BUSINESS WIRE)--Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative, plant-based health and wellness products, today announced that it will host a call for analysts and investors after market close on May 22, 2024. The company has scheduled a conference call for 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss recent strategic transactions. Interested participants can join the conference call using the following options: An audio-only webcast of t.

Arcadia Biosciences (RKDA) To Host Investor Call To Discuss Recent Transactions

Arcadia Biosciences' (RKDA) Q1 results benefit from a decline in operating expenses.

Arcadia Biosciences (RKDA) Shares Gain on Q1 Earnings Beat

DALLAS--(BUSINESS WIRE)--Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative, plant-based health and wellness products, and Above Food Corp., an innovative food company leveraging its vertically integrated supply chain to deliver differentiated ingredients and consumer products, announced today that Above Food will purchase the GoodWheatTM brand of better-for-you wheat products from Arcadia for $4 million net. “We see this as the beginning of a partnership between A.

Arcadia Biosciences (RKDA) Announces Sale of GoodWheatTM to Above Food Corp.

DALLAS--(BUSINESS WIRE)--Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative, plant-based health and wellness products, announced today it has sold its non-GMO Resistant Starch (RS) Durum Wheat trait to longtime partner Corteva Agriscience. Under the terms of the agreement, Arcadia will receive $4 million and retain the right to continue using Resistant Starch Durum in its GoodWheat portfolio of wheat products, including pastas and mac & cheese. Corteva will acq.

Arcadia Biosciences (RKDA) Announces Sale of Resistant Starch Durum Wheat Trait to Corteva Agriscience (CTVA)

Arcadia Biosciences, Inc. (NASDAQ:RKDA ) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants T.J. Schaefer - Chief Financial Officer Stan Jacot - President & Chief Executive Officer Conference Call Participants Ben Klieve - Lake Street Operator Thank you for standing by.

Arcadia Biosciences, Inc. (RKDA) Q1 2024 Earnings Call Transcript

Arcadia Biosciences (RKDA) came out with a quarterly loss of $1.78 per share versus the Zacks Consensus Estimate of a loss of $2.52. This compares to loss of $3.83 per share a year ago.

Arcadia Biosciences (RKDA) Reports Q1 Loss, Tops Revenue Estimates

DALLAS--(BUSINESS WIRE)--Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative, plant-based health and wellness products, today released its financial and business results for the first quarter of 2024. “Arcadia continued its positive trajectory in the first quarter of 2024,” said Stan Jacot, president and CEO. “Revenue continues to grow, both sequentially and year-over-year, and we have transitioned the topline to high-quality revenue that generates gross profit acro.

Arcadia Biosciences (RKDA) Announces First Quarter 2024 Financial Results and Business Highlights

Arcadia Biosciences (RKDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Arcadia Biosciences (RKDA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

DALLAS--(BUSINESS WIRE)--Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative, plant-based health and wellness products, today announced that it will release its financial and business results for the first quarter of 2024 after market close on May 9, 2024. The company has scheduled a conference call for 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss first-quarter results and key strategic achievements. Interested participants can join the conference call.

Arcadia Biosciences (RKDA) Announces Date of First Quarter 2024 Financial Results and Business Highlights Conference Call

AMN Healthcare Services

PROG Holdings

AMN, PRG and RKDA have been added to the Zacks Rank #5 (Strong Sell) List on April 22, 2024.

New Strong Sell Stocks for April 22nd

Arcadia Biosciences (RKDA) reports improved top-line results in the fourth quarter of 2023, which is aided by higher GoodWheat and GLA revenues.

Arcadia Biosciences (RKDA) Q4 Earnings Beat Mark, Sales Up Y/Y

Arcadia Biosciences, Inc. (RKDA) Q4 2023 Earnings Call Transcript

Arcadia Biosciences (RKDA) came out with a quarterly loss of $2.48 per share versus the Zacks Consensus Estimate of a loss of $2.68. This compares to loss of $6.31 per share a year ago.

News for Arcadia Biosciences Stock (RKDA)